Radiol Imaging Cancer 2021 Sep;3(5):e210048
From the Royal Marsden Hospital Foundation NHS Trust, Fulham Rd, London SW3 6JJ, England (C.M., B.S., D.L., D.M.K., K.B., C.P., A.R., K.D., J.C., V.M., S.S., J.W., W.J.G.O., M.F.K.); The Institute of Cancer Research, London, England (C.M., N.P., D.M.K., C.P., J.W., M.B., W.J.G.O., M.F.K.); Epsom and St Helier University Hospitals NHS Trust, Epsom, England (S.S.); Croydon University Hospital, Croydon, England (B.C.); University College London Hospital NHS Foundation Trust, London, England (C.K.); and Surrey and Sussex Healthcare NHS Trust, Redhill, England (P.K.).
Purpose To compare disease detection of myeloma using contemporary whole-body (WB) MRI and fluorine 18 (F) fluorodeoxyglucose (FDG) PET/CT protocols and to correlate imaging with laboratory estimates of disease burden, including molecular characteristics. Materials and Methods In this observational, prospective study, participants were recruited from November 2015 to March 2018 who had a diagnosis of myeloma, who were planned to undergo chemotherapy and autologous stem cell transplantation, and who underwent baseline WB-MRI and FDG PET/CT (ClinicalTrials.gov identifier NCT02403102). Read More